Counting Copies, Making Medicines: A Roadmap for the MSC-EV-microRNAome

Mesenchymal stromal cell–derived extracellular vesicles (MSC-EVs) are promising candidates for cell-free therapeutics, but the copy-number mathematics -most EVs contain fewer than one copy of a given microRNA (miRNA)- forces a reconsideration of mechanisms and development strategies. Translation will require disciplined adherence to MISEV2023 standards: definitions of transparent source and separation; absolute quantification of cargo by digital PCR (dPCR) or UMI-aware small RNA sequencing; and validated potency assays (e.g., NF-κB suppression, macrophage polarization) linked to critical quality attributes (CQAs). Dosing should evolve from particle/protein counts to a triad of particles, protein, and miRNA copies, ideally tied to activity-based units. Clean separations are essential to avoid misattributing effects to vesicles in the presence of non-vesicular RNA. Safety assessment, including TF/CD142 and thrombogenicity, must guide route selection. Manufacturing should standardize CPP-to-CQA control in TFF-based systems, while stability testing must minimize freeze–thaw cycles and validate lyophilization. The first approvable product will likely use local delivery, a small number of defined miRNAs, and copy-number-anchored dosing. The translational mandate is clear: count molecules, link counts to function, and dose based on biology.